Michael Nguyen

Nov 25, 2024 | aws.amazon.com | Sharon Yu |Michael Nguyen |Xin Huang |Saurabh Trikande

We’re excited to announce the availability of Meta Llama 3.1 8B and 70B inference support on AWS Trainium and AWS Inferentia instances in Amazon SageMaker JumpStart. Meta Llama 3.1 multilingual large language models (LLMs) are a collection of pre-trained and instruction tuned generative models. Trainium and Inferentia, enabled by the AWS Neuron software development kit (SDK), offer high performance and lower the cost of deploying Meta Llama 3.1 by up to 50%.

Nov 20, 2024 | advancingrna.com | AR Welch |Advancing RNA |Peter H. Calcott |Michael Nguyen

Webinar: Early Preclinical Development of mRNA/LNP projects - Setting Up Your Project for a Successful Transition to cGMP ManufacturingJoin us on December 2nd to explore mRNA construct development at Lonza, focusing on cGMP manufacturing, analytical advancements, and testing methods. Gain insights into the transition from research to manufacturing and the technologies shaping mRNA development for future projects. Click here to learn more.

Nov 9, 2024 | missionlocal.org | Michael Nguyen

Mission Local produces enterprise reporting on San Francisco's most critical issues: police reform, corruption, public health, housing and homelessness. Learn more about us, and donate below keep us reporting.

Oct 2, 2024 | advancingrna.com | AR Welch |Advancing RNA |Michael Nguyen

As I read through the FDA's draft platform designation guidance and listened to various panel discussions the past few months, a handful of additional observations and considerations came to mind that are important to reiterate for the RNA space, particularly as we advance into therapeutics development. Nutcracker's unique approach to scaling up to clinical manufacturing — which brings unique challenges compared to traditional biologics — relies on microfluidics.

Sep 11, 2024 | advancingrna.com | AR Welch |Advancing RNA |Michael Nguyen

As I’ve been reminded on a few different occasions, there is a difficult truth we may need to wrap our brains around in certain situations: Just because we can make an mRNA therapy for an indication, doesn’t necessary mean we should — or that the patient population will necessarily want it or be able to access it.